For chest pain patients, waiting even minutes in the emergency department can feel like an eternity. Clinicians need tools to help manage these patients, while improving clinical and operational outcomes. Those tools must be expertly designed, research proven diagnostic solutions, capable of meeting clinical performance demands that are continuously evolving.
Having a high-sensitivity troponin I assay that delivers actionable results in minutes can help clinicians manage chest pain patients with increased speed, insight and confidence:
- Offer improved cardiac patient care with a proven true high-sensitivity troponin I assay that meets the current AACC Academy/IFCC C-CB guideline recommendations1–4
- Have confidence in patient results at the low end of the assay range with precision that provides the ability to measure slight, yet critical, changes between serial troponin I values
- Obtain reliable results from a proven, trusted technology coupled with three new monoclonal antibodies
The Atellica® Solution’s streamlined STAT process has been shown to deliver actionable high-sensitivity troponin I results in 10 minutes.
Fully comprehensive cardiac test menu
High-sensitivity Troponin I, BNP and NT-proBNP* with results in minutes
Siemens Healthineers is proud to offer high-sensitivity troponin I across multiple systems, including the Atellica® IM Analyzer, ADVIA Centaur® System, Dimension® EXL™ Integrated Systems, and Dimension Vista® Intelligent Lab Systems.
*NT-proBNP not available for sale in the U.S.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
How Precise is Your Troponin?
Sensitivity and precision at the low end of the measuring range provides the ability to measure slight, yet critical, changes between serial troponin I values
Recent Studies Demonstrate Performance of High-sensitivity Troponin I Assay
Over the past 20 years the analytical sensitivity and precision of cardiac troponin (cTn) assays have improved for very low cTn concentrations. Compared to traditional cTn assays, high-sensitivity troponin I (hs-cTnI) assays can detect lower levels of troponin and smaller changes to a patient’s troponin levels, which may be an early indication of AMI.
A new literature compendium features recent articles offering guidance on the use of hs-cTnI assays, including sex-specific cutoffs, serial testing, and reporting units. These studies show that the Siemens Healthineers high-sensitivity troponin I assays are proven, true high-sensitivity cardiac troponin I assays that provide fast, accurate, and actionable test results.
See the results of these studies and the realized benefits to patients and hospitals.
View literature compendium (US)
PDF
View literature compendium (Outside the US)
PDF
Webinar: Successfully Implementing High-sensitivity Cardiac Troponin –
Collaboration Between Laboratory and Clinical Practice*
We are pleased to offer an exciting opportunity to hear from two globally recognized cardiac key opinion leaders, Professor Fred Apple and Professor Nicholas Mills as they discuss fast protocol strategies and evidence-based literature that supports implementation of high-sensitivity troponin testing in clinical practice. In addition, a thorough review of the controversial 2020 ESC NSTEMI guidelines and the NICE guidelines are provided.
Session Description:
- Review evidence-based literature that leads to implementation of high-sensitivity cardiac troponin testing into clinical practice
- Help healthcare providers understand diagnostic strategies using a high-sensitivity cardiac troponin assay
- Discuss the latest guidelines (ESC, NICE) pertaining to their interpretation perspectives
Speakers
Fred Apple, PhD
Nick Mills, PhD
Fred Apple, PhD
Co-Director Clinical & Forensic Toxicology Laboratory;
Professor, Laboratory Medicine & Pathology
Hennepin County Medical Center & University of Minnesota
Nick Mills, PhD
Consultant Interventional Cardiologist & Chair of Cardiology
Royal Infirmary of Edinburgh, Scotland & University of Edinburgh
1
Roffi M, et al./Task Force. Eur Heart J. 2015 ;37:267-315;
2
Amsterdam EA, et al. Circulation. 2014 ;130 :e344-426
3
Apple FS, et al. Clin Biochem. 2015 ;48 :201-3.
4
European Heart Journal (2018) 00, 1–33 EXPERT CONSENSUS DOCUMENT
Product availability may vary from country to country and is subject to varying regulatory requirements.
*The data mentioned for rapid-rule in/rule-out claims have not been submitted or reviewed by the FDA for Siemens Healthineers ADVIA Centaur TNIH and Atellica TNIH assays.